![Jin Hua Hu](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Jin Hua Hu
Director/Board Member at China Association of Health Education
Jin Hua Hu active positions
Companies | Position | Start | End |
---|---|---|---|
Shanghai Municipal People's Congress | Corporate Officer/Principal | 21/03/2010 | - |
China Association of Health Education | Director/Board Member | 14/09/2011 | - |
Career history of Jin Hua Hu
Former positions of Jin Hua Hu
Companies | Position | Start | End |
---|---|---|---|
MINGYUAN MEDICARE DEVELOPMENT CO., LTD. | Director/Board Member | - | 23/04/2014 |
Independent Dir/Board Member | 14/09/2011 | 23/04/2014 |
Statistics
International
China | 3 |
Hong Kong | 2 |
Operational
Director/Board Member | 2 |
Independent Dir/Board Member | 1 |
Corporate Officer/Principal | 1 |
Sectoral
Health Technology | 2 |
Government | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Private companies | 3 |
---|---|
Mingyuan Medicare Development Co. Ltd.
![]() Mingyuan Medicare Development Co. Ltd. BiotechnologyHealth Technology Mingyuan Medicare Development Co. Ltd. engages in provision of medicare solutions for the early detection and prevention of diseases particularly in China. It operates through the following segments: Protein Chips, Healthcare, Medical Centers Management, Individualized Target Therapy, and Bio-Drugs. The Protein Chips segment manufactures and distributes C-12 products to hospitals, medical centers, and life insurance companies in China. The Healthcare segment engages in the provision of sales and marketing campaign for HPV DNA testing kits and making important progress to register products for distribution to female patients at hospitals nationwide. The Medical Centers Management segment engages in the provision of healthcare services for residents living in cities. The Individualized Target Therapy segment specializes in molecular diagnostic kits for leukemia, lymphoma and individualised target cancer therapy. The Bio-Drugs segment engages in the development, production and commercialization of a new generation of non-specific nanotechnology immunomodulatory drugs known as non-cell Corynebacterium pavum products. The company was founded on May 8, 1989 and is headquartered in Hong Kong. | Health Technology |
Shanghai Municipal People's Congress | Government |
China Association of Health Education |
- Stock Market
- Insiders
- Jin Hua Hu
- Experience